Overview
TCA Cellular Therapy, LLC (TCA-CT) is a privately-held biotherapeutics company whose mission is to create and accelerate adult stem cell therapies and to develop next generation treatments for serious and life-threatening diseases. The company utilizes autologous (patient’s own) adult stem cells and TCA-CT-developed single and combination stem cell therapies to treat diseases of the cardiovascular, nervous, skeletal and muscular systems.
The U.S. Food and Drug Administration (FDA) has given TCA-CT consent to start several clinical trials to evaluate the effectiveness and safety use of adult stem cell products on patients suffering a variety of diseases.
Once trials have successfully demonstrated that the cell product is safe, effective and does not produce side effects (Phase III), the information will be examined by the FDA and post marketing studies will delineate the utilization of the stem cell product into humans as treatments for specific diseases. Accordingly, TCA-CT anticipates its first marketable biological product for the treatment of severe limb ischemia to be available as early as 2012.
The table below summarizes the potential United States patient populations which we believe may be amenable to cell or organ transplantation and represent target markets for products generated through our regenerative medicine technology.
Potential U.S. Patient Populations for Cell-Based Therapies
Medical Condition |
Number of Patients* |
Cardiovascular disease |
70 million |
Autoimmune disease |
50 million |
Diabetes |
18 million |
Osteoporosis |
10 million |
Cancer |
10 million |
Alzheimer’s disease |
4.5 million |
Parkinson’s disease |
1 million |
Burns (severe) |
1.1 million |
Spinal-cord injuries |
.25 million |
Birth defects |
.15 million/year |
* These estimates are based on the most current patient estimates published by the following organizations as of April 2005: the American Heart Association, the American Autoimmune Related Diseases Association, SEER (Surveillance, Epidemiology and End Result), American Burn Association, March of Dimes, the Alzheimer’s Association, the Alzheimer’s Disease Education & Referral Center (National Institute on Aging), the National Institutes of Health’s National Institute on Neurological Disorders and Stroke, the Foundation for Spinal Cord Injury Prevention, Care & Cure, the Centers for Disease Control and Prevention, the American Association of Diabetes Educators, the Northwest Parkinson’s Foundation and the Parkinson’s Action Network.
TCA –CT owns controlling interest in LifeSource Cryobank , a company specializing in the cryopreservation of umbilical cord blood and other adult stem cells.
TCA Cellular Therapy is focused on being the first to commercialize the most profitable application of regenerative medicine. We believe that regenerative medicine has the potential to revolutionize medicine by being able to produce human cells for use in a wide-array of novel and important therapies. The company is strategizing to position itself as a world-renowned, cutting edge research and service related company that is a leader in the emerging field of adult stem cell therapy.
Management:
Gabriel P. Lasala, MD, FACC, CEO
Jose J. Minguell, PhD, Scientific Director
Janet Jones, PhD, Chief Operations Officer
Investment Opportunities, Contact:
Janet Jones, PhD, COO
(985) 871-8227, ext. 820
e-mail: janet@tcaway.com
|
